Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus dexamethasone safety study in previously treated multiple myeloma
2006-002517-12Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Safety profile of lenalidomide plus dexamethasone. Started Jul 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-002517-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002517-12.